A prospective trial of HER2-breast cancer subjects treated with the anti-HER2 drug trastuzumab plus taxane-based neoadjuvant therapy showed that low residual uptake, defined as SUVmax < 2.1, following the first neoadjuvant cycle predicted PCR [43]. This evidence concerns the gene ERBB2 and breast cancer.